NLRP3 clinical progress

Among the pipeline-in-a-target opportunities afforded by NLRP3 across inflammatory conditions, cancer continues to lead the way, despite much of the field’s focus on autoimmunity and neurology. 

On Wednesday, La Jolla, Calif.-based EpicentRx Inc. reported data from the Phase II ROCKET trial of NLRP3 inhibitor RRx-001 plus irinotecan in advanced colorectal cancer, showing progression-free survival of 6.1 months vs. 1.7 months (p=0.003) with regorafenib, the standard of care. Median overall survival (OS) was 8.6 months in the treatment arm vs. 4.7 months with SOC. Objective response rates (ORRs) were 20.8% for RRx-001 and irinotecan chemotherapy vs. 0% for regorafenib...